Joyce Matsumoto
Neurology · Los Angeles, CANPI 1194868182
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Mallinckrodt Enterprises LLC at 33.5% of the total. Reporting peaked in 2019 at $10,762 and has fallen 86.9% since, to $1,410 in 2025.
Across 150 payments — averaging $153.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$8K
- Jazz Pharmaceuticals Inc.$7K
- UCB, Inc.$2K
- Zimmer Biomet$1K
- Neuropace, Inc.$1K
- Eisai Inc.$555
- plus $3K from 15 others
What the payments were for
- Consulting fees$12,10853%
- Travel & lodging$2,72312%
- Food & beverage$8,16836%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 9 | $7,704 |
| Jazz Pharmaceuticals Inc. | 16 | $6,557 |
| UCB, Inc. | 41 | $2,309 |
| Zimmer Biomet | 10 | $1,326 |
| Neuropace, Inc. | 16 | $1,287 |
| Eisai Inc. | 7 | $555 |
| Neurelis, Inc. | 11 | $503 |
| SK Life Science, Inc. | 7 | $401 |
| Sentynl Therapeutics, Inc. | 1 | $308 |
| Pyros Pharmaceuticals, Inc. | 3 | $288 |
| Greenwich Biosciences, Inc. | 5 | $261 |
| Biocodex, Inc. | 4 | $249 |
| Amneal Pharmaceuticals LLC | 1 | $245 |
| Livanova USA, Inc. | 5 | $217 |
| Immedica Pharma US, Inc. | 5 | $197 |
| Sunovion Pharmaceuticals Inc. | 4 | $192 |
| Biomarin Pharmaceutical Inc. | 1 | $129 |
| Aquestive Therapeutics, Inc. | 1 | $125 |
| Zogenix Inc. | 1 | $93 |
| Acadia Pharmaceuticals Inc | 1 | $29 |
| Upsher-smith Laboratories LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$7,522
- Epidiolex$1,077
- ROSA$1,043
- RNS Neurostimulator Kit$607
- Fintepla$368
- VIGPODER$249
- Fycompa$249
- VALTOCO$237
- RNS System$146
- ZTALMY$140
- DIACOMIT$133
- Brineura$129
- Vimpat$126
- SYMPAZAN$125
- Briviact$125
- VNS Therapy$113
How this compares
$23,000 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 11 | $33,954 |
| Clobazam | 35 | $12,357 |
| NayzilamMidazolam | 11 | $7,832 |
| Diazepam | 17 | $4,897 |
| Lamotrigine | 18 | $1,100 |
| Baclofen | 12 | $256 |
| Clonidine Hcl | 13 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Nayzilam | $2,309 | $7,83211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.